In the world of specialty pharmaceuticals, a breakthrough therapy is only as powerful as a patient’s ability to access and adhere to it. As the industry prepares to gather at Asembia 2025, patient services are taking center stage.
The year 2024 marked a pivotal moment for the pharmaceutical industry as stakeholders prepared for the Drug Supply Chain Security Act (DSCSA) interoperability deadline on November 27.
Karuna Therapeutics - A Bristol Myers Squibb Company, a cutting-edge neuroscience company, was in the midst of preparing for a critical U.S. product launch when it encountered the complex regulatory requirements of DSCSA compliance.
Exelixis, a leader in biopharmaceutical innovation, is dedicated to developing therapies that meet critical medical needs. However, as DSCSA requirements and regulations continued to evolve, Exelixis encountered obstacles in maintaining a compliance framework that could keep pace with its rapid growth.
The Informa Trade & Channel Strategies Conference has long been a key venue for addressing the challenges and opportunities shaping the pharmaceutical trade landscape.
